If you missed the first post, I’m running a six month experiment to see whether ChatGPT or Deepseek could beat the market with a micro-cap portfolio. Before the first update, I have to be real with you guys. DeepSeek did bad. Like -20% first week bad. I realize if nothing changes it’s going to a six month humiliation ritual for DeepSeek. So, I will be cutting DeepSeek out of the experiment. Your 20% downturn in five days will never be forgotten, DeepSeek. I will be cutting DeepSeek out of the experiment I will be cutting DeepSeek out of the experiment . Overall, ChatGPT had a first great week! It even outperformed the Russell 2000. CSAI (Cloudastructure Inc) was the MVP with a 12% increase. However, It’s other two picks stayed stagnant. Of course, we already know how DeepSeek’s went. ChatGPT’s Performance: +6.72%​ ChatGPT’s Performance: +6.72%​ DeepSeek’s Performance: -18.06%​ DeepSeek’s Performance: -18.06%​ Now for ChatGPT’s portfolio update: ChatGPT’s Changes: ChatGPT’s Changes: ABEO (Abeona Therapeutics) – HoldFDA-approved gene therapy launching now. $225M cash. Recently added to Russell 2000. Undervalued. Big upside if early sales impress.CADL (Candel Therapeutics) –  HoldStrong Phase 3 cancer data. $100M cash runway. Multiple ongoing trials. Q4 glioma data could be a major catalyst.AZTR (Azitra, Inc.) – Buy~$4M market cap. Phase II/III trial for rare skin disease (RDEB) ends Q4. Interim data showed 60% wound healing vs. 15% placebo. High-risk moonshot with potential for 10x+ upside. ABEO (Abeona Therapeutics) – Hold ABEO (Abeona Therapeutics) Hold FDA-approved gene therapy launching now. $225M cash. Recently added to Russell 2000. Undervalued. Big upside if early sales impress. CADL (Candel Therapeutics) –  Hold CADL (Candel Therapeutics) Hold Strong Phase 3 cancer data. $100M cash runway. Multiple ongoing trials. Q4 glioma data could be a major catalyst. AZTR (Azitra, Inc.) – Buy AZTR (Azitra, Inc.) Buy ~$4M market cap. Phase II/III trial for rare skin disease (RDEB) ends Q4. Interim data showed 60% wound healing vs. 15% placebo. High-risk moonshot with potential for 10x+ upside. Sold: CSAI – Lacked short-term catalyst. Capital reallocated into AZTR for higher return potential. Sold: Cash Remaining: ~$20 Cash Remaining: Thought Process: Thought Process: Clear Q3–Q4 catalysts across all holdingsHigh short interest could fuel squeeze ralliesFocused on biotech for asymmetric return potential Clear Q3–Q4 catalysts across all holdings High short interest could fuel squeeze rallies Focused on biotech for asymmetric return potential Will ChatGPT continue to outperform? Will it fall into the depths with DeepSeek? Check back next week for the update and thank you for reading!

Can ChatGPT Outperform the Market? A Finance Nerd's Quest to Find Out

About Author

Comments

TOPICS

THIS ARTICLE WAS FEATURED IN

Related Stories

Untitled Story

Can ChatGPT Outperform the Market? Changes Going Forward

Your AI Agent Is Too Slow—Here’s How to Fix It

Forget Choosing a Model—Let the AI Choose You

Vibe Coding with ChatGPT-5 in Cursor IDE

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Can ChatGPT Outperform the Market? Changes Going Forward

Your AI Agent Is Too Slow—Here’s How to Fix It

Forget Choosing a Model—Let the AI Choose You

Vibe Coding with ChatGPT-5 in Cursor IDE

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Light-Mode

Classic

Newspaper

Dark-Mode

Neon Noir

Minty

HN StartUps